Wall Street Zen Downgrades Spero Therapeutics (NASDAQ:SPRO) to Hold

Spero Therapeutics (NASDAQ:SPRO) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

A number of other research firms have also recently issued reports on SPRO. Zacks Research cut shares of Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $5.00.

Spero Therapeutics Trading Up 0.9%

Shares of NASDAQ SPRO opened at $2.35 on Friday. The company has a market capitalization of $132.40 million, a P/E ratio of -2.97 and a beta of 1.48. Spero Therapeutics has a 12 month low of $0.51 and a 12 month high of $3.22. The stock has a 50 day moving average of $2.35 and a 200-day moving average of $2.31.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.12. Spero Therapeutics had a negative return on equity of 125.91% and a negative net margin of 108.11%.The business had revenue of $5.44 million during the quarter, compared to the consensus estimate of $12.00 million. Analysts predict that Spero Therapeutics will post -1.2 EPS for the current fiscal year.

Insider Transactions at Spero Therapeutics

In other Spero Therapeutics news, insider Esther Rajavelu sold 40,270 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $2.37, for a total transaction of $95,439.90. Following the transaction, the insider owned 869,450 shares in the company, valued at $2,060,596.50. This represents a 4.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Spero Therapeutics

Several institutional investors have recently made changes to their positions in SPRO. Capital Asset Advisory Services LLC acquired a new stake in Spero Therapeutics during the second quarter worth approximately $94,000. Axxcess Wealth Management LLC bought a new stake in shares of Spero Therapeutics during the 2nd quarter valued at $94,000. XTX Topco Ltd acquired a new stake in shares of Spero Therapeutics during the 2nd quarter worth $100,000. Quadrature Capital Ltd bought a new position in shares of Spero Therapeutics in the second quarter worth $90,000. Finally, Invesco Ltd. acquired a new position in Spero Therapeutics in the second quarter valued at about $43,000. 25.60% of the stock is currently owned by institutional investors.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.